Please assess the completion status of the following clinical trial:

Trial Title: Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy male subjects,aged 18 to 40 years of age included and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests~Exclusion Criteria:~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~* Known history or current clinically significant ECG abnormalities or arrhythmias.~* Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, or other conditions which could interfere with the interpretation of the study results or compromise the health of the subjects.~* Sexually active males must use a condom during intercourse while taking drug and for al least 4 weeks after stopping study medication and should not father a child during this period.~* History of malaria or residence in a malaria-endemic area over a period of 6 months before study entry. - Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk or render the subject unable to meet requirements of the protocol.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- KAF156 800 mg pre-challenge (Type: EXPERIMENTAL): Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 800 mg pre-challenge (Type: PLACEBO_COMPARATOR): Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
- KAF156 800 mg post-challenge (Type: EXPERIMENTAL): Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 800 mg post-challenge (Type: PLACEBO_COMPARATOR): Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- KAF156 300 mg post-challenge (Type: EXPERIMENTAL): Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 300 mg post-challenge (Type: PLACEBO_COMPARATOR): Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- KAF156 100 mg post-challenge (Type: EXPERIMENTAL): Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 100 mg post-challenge (Type: PLACEBO_COMPARATOR): Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- KAF156 20 mg post-challenge (Type: EXPERIMENTAL): Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 20 mg post-challenge (Type: PLACEBO_COMPARATOR): Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- KAF156 50 mg post-challenge (Type: EXPERIMENTAL): Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
- Placebo 50 mg post-challenge (Type: PLACEBO_COMPARATOR): Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos

Based on this trial design, predict the completion outcome and termination type (if applicable).